Alkermes ALKS Medicaid Rebate — Accrued Sales Discounts Allowances And Reserves
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept alks:AccruedSalesDiscountsAllowancesAndReserves.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's medicaid rebate — accrued sales discounts allowances and reserves.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's medicaid rebate — accrued sales discounts allowances and reserves?
- Alkermes (ALKS) reported medicaid rebate — accrued sales discounts allowances and reserves of $189.03M in Q1 2026.
- How has Alkermes's medicaid rebate — accrued sales discounts allowances and reserves changed year-over-year?
- Alkermes's medicaid rebate — accrued sales discounts allowances and reserves decreased by 1.3% year-over-year, from $191.47M to $189.03M.
- What is the long-term trend for Alkermes's medicaid rebate — accrued sales discounts allowances and reserves?
- Over 3 years (2022 to 2025), Alkermes's medicaid rebate — accrued sales discounts allowances and reserves has grown at a -2.3% compound annual growth rate (CAGR), from $813.84M to $757.99M.
- What does medicaid rebate — accrued sales discounts allowances and reserves mean?
- This metric represents the estimated financial liability accrued for rebates owed to state Medicaid programs based on the sales of specific pharmaceutical products. It reflects the company's obligation to provide price concessions to government payers as mandated by regulatory requirements for drug reimbursement. These accruals are critical for accurately reporting net revenue by accounting for the difference between gross sales and the expected net realization after government-mandated discounts.